HOUSTON, April 4, 2019 /PRNewswire/ -- Soliton, Inc.,
(NASDAQ: SOLY) ("Soliton" or the "Company"), a medical device
company with a novel and proprietary platform technology licensed
from The University of Texas on behalf
of the MD Anderson Cancer Center ("MD Anderson"), today announced
that the European Patent Office has issued a notice of grant for
its European Patent Application No. 14760628.9 based on
International Application No.PCT/US2014/021746; Entitled "Rapid
Pulse Electrohydraulic (Eh) Shockwave Generator Apparatus And
Methods For Medical And Cosmetic Treatments," by Christopher C. Capelli. The Patent is eligible
for validation in 38 European countries.
Join our more than 200K fans here
to follow the Company: https://soly-investors.com
Clinical trials for tattoo removals have demonstrated that using
the Company's RAP device, in conjunction with a Q-Switched laser,
allows for multiple passes of laser treatment in a single treatment
session. The current standard of care for tattoo removal is to use
a Q-Switched laser to ablate the tattoo ink particles into pieces
small enough for the body's natural processes to remove them.
Independent studies have shown this standard treatment requires on
average ten or more office visits to achieve acceptable results. In
our own clinical trial using the RAP device in conjunction with a
Q-Switched laser, patients experienced 75% to 100% removal of their
tattoos in just three office visits.
Dr. Chris Capelli, President and
CEO of Soliton, commented, "We now have eight patent families
pending relating to the technologies that makes our RAP device and
certain variations possible, with still more potential patent
applications under way. Our patent portfolio is comprised of five
pending U.S. patent applications, 11 granted and 33 pending foreign
counterpart patent applications, and four pending PCT patent
applications, each of which we either own directly or we are the
exclusive licensee."
Dr. Capelli continued, "This latest patent protection is
particularly important because of the breadth of countries
throughout Europe impacted by the
grant. Tattoo removal is a global opportunity, with worldwide sales
in the segment estimated to be approximately $4.8 billion annually by 2023."
About Soliton, Inc.
Soliton, Inc. is a medical device company with a novel and
proprietary platform technology licensed from MD Anderson. The
Company's first planned commercial product is designed to use rapid
pulses of designed acoustic shockwaves in conjunction with existing
lasers to accelerate the removal of unwanted tattoos (RAP device).
In addition, higher energy versions of acoustic pulse devices are
in early stages of development for potential stand-alone treatment
of cellulite and other indications. Both products are
investigational and are not available for sale in the United States.
For more information about the Company, please
visit: http://www.soliton.com
Forward-Looking Statements
Some of the statements in this release are forward-looking
statements within the meaning of Section 27A of the Securities Act
of 1933, Section 21E of the Securities Exchange Act of 1934 and the
Private Securities Litigation Reform Act of 1995, which involve
risks and uncertainties. Forward-looking statements in this press
release include, without limitation, the ability of Soliton to
secure adequate patent protection and the estimated potential size
of the global tattoo market. These statements relate to future
events, future expectations, plans and prospects. Although Soliton
believes that the expectations reflected in such forward-looking
statements are reasonable as of the date made, expectations may
prove to have been materially different from the results expressed
or implied by such forward-looking statements. Soliton has
attempted to identify forward-looking statements by terminology
including ''believes,'' ''estimates,'' ''anticipates,''
''expects,'' ''plans,'' ''projects,'' ''intends,'' ''potential,''
''may,'' ''could,'' ''might,'' ''will,'' ''should,''
''approximately'' or other words that convey uncertainty of future
events or outcomes to identify these forward-looking statements.
These statements are only predictions and involve known and unknown
risks, uncertainties, and other factors, including those discussed
in our SEC filings, including under the heading "Item 1A. Risk
Factors" in the Form 10-K for year ended December 31, 2018 we filed with the SEC and
updated from time to time in our Form 10-Q filings and in our other
public filings with the SEC. Any forward-looking statements
contained in this release speak only as of its date. Soliton
undertakes no obligation to update any forward-looking statements
contained in this release to reflect events or circumstances
occurring after its date or to reflect the occurrence of
unanticipated events.
CONTACT:
|
Joe Dorame, Joe
Diaz & Robert Blum
|
|
Lytham Partners,
LLC
|
|
602-889-9700
|
|
soly@lythampartners.com
|
View original content to download
multimedia:http://www.prnewswire.com/news-releases/soliton-receives-european-patent-for-acoustic-shockwave-technology-300824456.html
SOURCE Soliton, Inc.